Point of Care Diagnostics Testing Companies

Roche acquires LumiraDx for up to $350 million: This move strengthens Roche's presence in the POCT market, particularly in COVID-19 testing and chronic disease management.

Abbott Laboratories partners with Cepheid for sepsis testing: This collaboration combines Abbott's POC instruments with Cepheid's molecular test technology to offer quicker and more accurate sepsis diagnosis in critical care settings.

Becton, Dickinson and Company (BD) invests in Lumos Diagnostics: This strategic partnership focuses on developing and commercializing innovative POCT platforms for infectious diseases and chronic conditions.

QuantuMDx launches a new respiratory panel test: This rapid test simultaneously detects SARS-CoV-2, Flu A/B, and RSV, providing valuable information for managing respiratory illnesses at the point of care.

Boditech Med enters a strategic partnership with Novo Integrated Sciences: This collaboration expands Boditech's biomarker-based rapid testing product line across North America.

Roche launches the Cobas Pulse System in select countries: This next-generation system offers connected POCT solutions for professional blood glucose management.

• Abbott Laboratories (US)


• Siemens Healthineers GmbH (Germany)


• Chembio Diagnostics, Inc.(US)


• Hoffmann-La Roche Ltd (Switzerland)


• Johnson & Johnson Services, Inc. (US)


• Becton, Dickinson and Company (US)


• Danaher Corporation (US)


• PTS Diagnostics (US)


• Nova Biomedical (US)


• QuidelCorporation (US)


• Sekisui Diagnostics (US)


• Trinity Biotech (Ireland)


• Instrumentation Laboratory Company (Werfen) (US)


• EKF Diagnostics Holdings plc (UK)